BioNTech SE
(WBO:BNTX)
€
108.9
0.6 (0.55%)
Market Cap: 26.09 Bil
Enterprise Value: 9.63 Bil
PE Ratio: 0
PB Ratio: 1.29
GF Score: 62/100 BioNTech SE at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 04:30PM GMT
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello, and welcome to all to the UBS Global Healthcare Conference. My name is Navin Jacob, senior analyst, covering large-cap pharma and smid-cap biotech. Our next presentation and fireside chat is with BioNTech, which had a very successful IPO late 2019. I'm very happy to have with me today Chief Strategic Officer, Ryan Richardson. Ryan, thank you for joining us today.
Ryan Richardson
BioNTech SE - Chief Strategy Officer, MD & Member of Management Board
Thank you, Navin.
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
And so -- exactly. So folks on the line, Ryan is going to walk through a few slides here, just to give some backdrop on BioNTech for folks who are not familiar with the name. And then after that, we're going to have a little fireside chat. Go ahead, Ryan.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot